ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2026
A single-institution retrospective review of patients treated with single-fraction 28 Gy SBRT to lung tumors.
Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Single-fraction stereotactic body radiotherapy (SBRT) has been used to treat lung tumors. However, there is heterogeneity in the prescribed dose. We performed a single-institution, retrospective review to assess the outcomes associated with single-fraction 28 Gy SBRT to cancers in the lung. Materials and methods: A chart review was performed on all patients treated with 28 Gy in 1 fraction to the lung in our institution between February 2022 and April 2023. Patient and tumour characteristics were obtained. Outcomes pertaining to local control, and acute and late toxicities occurring after treatment were obtained from radiological reports and patient charts. Results: 130 patients were reviewed and analyzed. The median follow-up in this cohort was 22 months. 81% of the patients were treated for a primary lung tumour. Estimated Kaplan-Meier 1- and 2-year local control rates were 95.7% (primary: 97.9%, metastases: 89.1%) and 86.9% (primary: 87.6%, metastases: 76.3%), respectively. 21% of patients experienced acute grade 1-2 toxicities, most commonly fatigue and temporary chest wall pain. 18% of patients experienced late grade 1-2 toxicities, most commonly asymptomatic pneumonitis and chest wall pain. There was no reported grade 3 or higher acute or late toxicities. Conclusions: Our review supports the safety and value of 28 Gy delivered in one fraction. Prospective trials with long-term follow-up are needed to define the role and optimal dose of single-fraction ablative SBRT to lung tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.